Bristol Myers Squibb (CELG-RI) Operating Expenses (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Operating Expenses of $8.9 billion for Q2 2026, down 15.33% year-over-year from $10.5 billion in Q2 2025, and up 7.72% quarter-over-quarter from $8.2 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Operating Expenses (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Operating Expenses for 18 consecutive years, with $8.9 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Expenses fell 15.33% year-over-year to $8.9 billion; the TTM figure through Jun 2026 stood at $37.3 billion (down 9.32% YoY), while the FY2025 annual figure was $38.9 billion, down 31.43% from the prior year.
- Operating Expenses advanced to $8.9 billion in Q2 2026 per CELG-RI's latest filing, from $8.2 billion in the prior quarter.
- Across five years, Operating Expenses topped out at $23.4 billion in Q1 2024 and bottomed at $8.2 billion in Q1 2025.
- Historically, Operating Expenses has averaged $10.4 billion across 5 years, with a median of $9.7 billion in 2022.
- Annual changes were most pronounced in 2024 — Operating Expenses soared 172.92% — and 2025, when it sank 64.8%.
- Bristol Myers Squibb's Operating Expenses stood at $9.5 billion in 2022, then climbed by 2.68% to $9.8 billion in 2023, then increased by 24.12% to $12.2 billion in 2024, then fell by 9.33% to $11.0 billion in 2025, then dropped by 19.44% to $8.9 billion in 2026.
- Business Quant data shows CELG-RI's Operating Expenses at $8.9 billion in Q2 2026, $8.2 billion in Q1 2026, and $11.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 8.89 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.89 Bn |
| Mar 31, 2026 | 8.25 Bn |
| Dec 31, 2025 | 11.03 Bn |
| Sep 30, 2025 | 9.11 Bn |
| Jun 30, 2025 | 10.50 Bn |
| Mar 31, 2025 | 8.23 Bn |
| Dec 31, 2024 | 12.17 Bn |
| Sep 30, 2024 | 10.22 Bn |
| Jun 30, 2024 | 10.92 Bn |
| Mar 31, 2024 | 23.38 Bn |
| Dec 31, 2023 | 9.80 Bn |
| Sep 30, 2023 | 8.83 Bn |
| Jun 30, 2023 | 9.37 Bn |
| Mar 31, 2023 | 8.57 Bn |
| Dec 31, 2022 | 9.55 Bn |
| Sep 30, 2022 | 9.01 Bn |
| Jun 30, 2022 | 9.93 Bn |
| Mar 31, 2022 | 9.96 Bn |
| Dec 31, 2021 | 10.13 Bn |
| Sep 30, 2021 | 9.47 Bn |